March 18, 2008 – Today Bristol-Myers Squibb Medical Imaging introduced its new name by launching Lantheus Medical Imaging, marking the first time in the company’s 50-year history that it will operate as an independent company.
The launch builds on the momentum created by the acquisition of the business by Avista Capital Partners in January of this year. The Massachusetts-based company, acquired by Avista Capital Partners in January 2008, will continue to provide medical imaging products for nuclear and ultrasound cardiovascular diagnostic imaging procedures, including Cardiolite (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), DEFINITY Vial for (Perflutren Lipid Microsphere) Injectable Suspension and TechneLite (Technetium Tc99m Generator).
Lantheus Medical Imaging’s new President and CEO Don Kiepert said, “Lantheus Medical Imaging is well-positioned for growth with a market-leading product portfolio, promising pipeline and a world-class organization committed to the field of medical imaging. Our people are passionate about developing innovative, clinically meaningful diagnostic tools that enhance and improve patient care.”
Before joining Lantheus Medical Imaging, Kiepert was the founder and former Chairman, CEO and President of Point Therapeutics since 1996. Prior to that he was president and CEO of Chartwell Home Therapies, a home infusion services company, from 1989 to 1996. Kiepert also started and managed several health care companies and worked in various management positions at Baxter Travenol, Inc. Kiepert received his M.S. degree in clinical pharmacy from Purdue University.
For more information: www.lantheus.com
July 09, 2024 
